Market capitalization is the total value the stock market puts on a company: its share price multiplied by the number of shares outstanding. Each point here is the share count reported in a filing multiplied by the closing price on that filing date, adjusted for later stock splits, so the history moves when a new filing arrives rather than with each day's trading. A larger market cap means investors collectively value the company more highly; by itself it says nothing about profit or debt. Annual points keep the latest observation in each calendar year.
BridgeBio Pharma, Inc. market cap for the quarter ending 2026-08-03 was $15.64B, a 76.63% increase year-over-year.
BridgeBio Pharma, Inc. market cap for the quarter ending 2026-06-30 was $14.55B, a 76.26% increase year-over-year.
BridgeBio Pharma, Inc. market cap for the quarter ending 2026-04-30 was $13.92B, a 114.51% increase year-over-year.
BridgeBio Pharma, Inc. market cap for the quarter ending 2026-03-31 was $14.54B, a 121.56% increase year-over-year.
BridgeBio Pharma, Inc. market cap for fiscal 2026 was $15.64B.
BridgeBio Pharma, Inc. market cap for fiscal 2025 was $14.9B, a 185.76% increase from fiscal 2024.
BridgeBio Pharma, Inc. market cap for fiscal 2024 was $5.21B, a 26.22% decline from fiscal 2023.
BridgeBio Pharma, Inc. market cap for fiscal 2023 was $7.07B, a 515.81% increase from fiscal 2022.